Societal CDMO, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-29: Form 8-K; Period of report 2017-12-29; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2017-11-28: Form 8-K; Period of report 2017-11-28; Description 8.01 Other Events; Details 8.01.
- 2017-11-20: Form 8-K; Period of report 2017-11-17; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2017-11-14: Form 8-K; Period of report 2017-11-14; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-29 | 8-K | 2017-12-29 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d515486d8k.htm |
| 2017-11-28 | 8-K | 2017-11-28 | 8.01 Other Events | 8.01 On November 28, 2017, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d468805d8k.htm |
| 2017-11-20 | 8-K | 2017-11-17 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 1.02 The Company used proceeds from the Term A Loan to repay in full all outstanding indebtedness under the OrbiMed Credit Agreement and terminate the OrbiMed Credit Agreement, which had provided the Company with a $50 million term loan due on April 22, 2020, at an interest rate of three month LIBOR, with a 1.0% floor plus 14.0%. 2.03 The information set forth under Item 1.01 above is incorporated into this Item 2.03 by reference. 3.02 This information in Item 1.01 above regarding the Warrants is incorporated into this Item 3.02 by reference. | d498708d8k.htm |
| 2017-11-14 | 8-K | 2017-11-14 | 8.01 Other Events | 8.01 On November 14, 2017, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d493516d8k.htm |
| 2017-11-09 | 8-K | 2017-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2017. | d683848d8k.htm |
| 2017-10-11 | 8-K | 2017-10-11 | 8.01 Other Events | 8.01 On October 11, 2017, Recro Pharma, Inc. (the “Company”) updated its corporate presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d474247d8k.htm |
| 2017-10-05 | 8-K | 2017-10-05 | 8.01 Other Events | 8.01 On October 5, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing the PDUFA Date for IV Meloxicam 30mg. | d470404d8k.htm |
| 2017-09-28 | 8-K | 2017-09-28 | 8.01 Other Events | 8.01 On September 28, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has accepted for review its New Drug Application for intravenous meloxicam 30mg for the management of moderate to severe pain. | d465100d8k.htm |
| 2017-09-19 | 8-K | 2017-09-19 | 8.01 Other Events | 8.01 On September 19, 2017, Recro Pharma, Inc. (the “Company”) updated its corporate presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d429310d8k.htm |
| 2017-09-05 | 8-K | 2017-09-05 | 8.01 Other Events | 8.01 On September 5, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing that it will present three poster presentations at PAINWeek 2017, taking place September 5-9, 2017, in Las Vegas, NV. | d453877d8k.htm |
| 2017-08-21 | 8-K | 2017-08-21 | 8.01 Other Events | 8.01 On August 21, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing the appointment of Jyrki Mattila, M.D., Ph.D., as Executive Vice President of Business Development of the Company. | d436859d8k.htm |
| 2017-08-17 | 8-K | 2017-08-17 | 8.01 Other Events | 8.01 On August 17, 2017, Recro Pharma, Inc. (the “Company”) updated its corporate presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d421576d8k.htm |
| 2017-08-10 | 8-K | 2017-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2017. | d621142d8k.htm |
| 2017-07-31 | 8-K | 2017-07-31 | 8.01 Other Events | 8.01 On July 31, 2017, Recro Pharma, Inc. issued a press release announcing that it has submitted a New Drug Application to the U.S. Food and Drug Administration for its lead investigational product candidate intravenous (IV) meloxicam 30mg for the treatment of moderate to severe, acute postoperative pain. | d319995d8k.htm |
| 2017-07-20 | 8-K | 2017-07-14 | 1.01 Entry into a Material Definitive Agreement | 1.01 On July 14, 2017, Recro Pharma, Inc., through its subsidiary Recro Ireland Limited (collectively, the “Company”) entered into a Master Manufacturing Services Agreement (the “Master Agreement”) and a related Product Agreement (the “Product Agreement,” and together with the Master Agreement, the “Agreements”) with Patheon UK Limited (“Patheon”), each effective as of July 14, 2017. | d428324d8k.htm |
| 2017-07-18 | 8-K | 2017-07-17 | 8.01 Other Events | 8.01 On July 17, 2017, Recro Pharma, Inc. (the “Company”) updated its corporate presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d419935d8k.htm |
| 2017-07-05 | 8-K | 2017-06-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 30, 2017, Recro Pharma, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Cornell University, as represented by its Center for Technology Licensing (“Cornell”), pursuant to which Cornell granted the Company a worldwide, exclusive, sublicensable, royalty-bearing license in Cornell’s patents and other intellectual property relating to an intermediate-acting neuromuscular blocking agent, a short-acting neuromuscular blocking agent and a reversal agent proprietary to the blocking agents (collectively, the “Compounds”), to develop, manufacture and sell the Compounds. | d409526d8k.htm |
| 2017-06-09 | 8-K | 2017-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As of June 5, 2017, Donna Nichols, the Chief Accounting Officer and Controller of Recro Pharma, Inc. (the “Company”) is no longer employed with the Company. | d332306d8k.htm |
| 2017-06-08 | 8-K | 2017-06-08 | 8.01 Other Events | 8.01 On June 8, 2017, Recro Pharma, Inc. (the “Company”) updated its corporate presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d391832d8k.htm |
| 2017-05-18 | 8-K | 2017-05-12 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 12, 2017, Recro Pharma, Inc. (the “Company”) held its 2017 Annual Meeting of Shareholders (the “Annual Meeting”). | d307670d8k.htm |
| 2017-05-18 | 8-K | 2017-05-18 | 7.01 Regulation FD Disclosure | 7.01 On May 18, 2017, Recro Pharma, Inc. (the “Company”) announced that it will present a poster presentation entitled “Efficacy and Safety of N1539, Intravenous Meloxicam, in a Phase 3 Study of Subjects with Moderate to Severe Pain following Bunionectomy” at the American Pain Society 36th Annual Scientific Meeting, taking place May 17-20, 2017, in Pittsburgh, PA. | d382822d8k.htm |
| 2017-05-11 | 8-K | 2017-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2017. | d377463d8k.htm |
| 2017-05-09 | 8-K | 2017-05-09 | 8.01 Other Events | 8.01 On May 9, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing successful top-line results from its Phase III safety study evaluating intravenous (IV) meloxicam (30mg bolus injection) following major surgery. | d394254d8k.htm |
| 2017-04-05 | 8-K | 2017-04-05 | 8.01 Other Events | 8.01 On April 5, 2017, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d317414d8k.htm |
| 2017-03-07 | 8-K | 2017-03-06 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On March 6, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2016. 8.01 On March 6, 2017, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. | d337732d8k.htm |
| 2017-03-06 | 8-K | 2017-03-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On March 2, 2017, Dr. Abraham Ludomirski, a member of the Board of Directors (the “Board”) of Recro Pharma, Inc. (the “Company”), notified the Company of his intention to resign from the Board effective March 3, 2017. 8.01 On March 6, 2017, the Company issued a press release announcing the resignation of Dr. Ludomirski from the Board and the appointment of Mr. Reasons as a director. | d337796d8k.htm |
| 2017-02-27 | 8-K | 2017-02-27 | 8.01 Other Events | 8.01 On February 27, 2017, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d310602d8k.htm |
| 2017-01-06 | 8-K | 2017-01-06 | 8.01 Other Events | 8.01 On January 6, 2017, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d310486d8k.htm |